Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial
Yunpeng Yang(State Key Laboratory of Oncology in South China), Song Qu(The People's Hospital of Guangxi Zhuang Autonomous Region), Jingao Li(Jiangxi Provincial Cancer Hospital), Chaosu Hu(Fudan University Shanghai Cancer Center), Mingjun Xu(First Affiliated Hospital of Gannan Medical University), Weidong Li(Guangzhou Medical University), Ting Zhou(State Key Laboratory of Oncology in South China), Liangfang Shen(Central South University), Hui Wu(Zhengzhou University), Jinyi Lang(Sichuan Cancer Hospital), G. Hu(Huazhong University of Science and Technology), Zhanxiong Luo(Liuzhou General Hospital), Zhichao Fu, Shenhong Qu(The People's Hospital of Guangxi Zhuang Autonomous Region), Weineng Feng(First People's Hospital of Foshan), Xiaozhong Chen(Zhejiang Cancer Hospital), Shaojun Lin(Fujian Provincial Cancer Hospital), Weimin Zhang(Third Affiliated Hospital of Southern Medical University), Xiaojiang Li, Yan Sun(Peking University Cancer Hospital), Zhixiong Lin(Cancer Hospital of Shantou University Medical College), Qin Lin(First Affiliated Hospital of Xiamen University), Lei Feng(Zhongshan People's Hospital), Jianting Long(Sun Yat-sen University), Jinsheng Hong(Fujian Medical University), Xiaoming Huang(Sun Yat-sen University), Lingzhi Zeng(Nanchang University), Peiguo Wang(Tianjin Medical University Cancer Institute and Hospital), Xiaohui He(Chinese Academy of Medical Sciences & Peking Union Medical College), Ben Zhang(Jiangsu Hengrui Medicine (China)), Qing Yang(Jiangsu Hengrui Medicine (China)), Xiao‐Jing Zhang(Jiangsu Hengrui Medicine (China)), Jianjun Zou(Jiangsu Hengrui Medicine (China)), Wenfeng Fang(Sun Yat-sen University), Li Zhang(Sun Yat-sen University)
Cited by 447
Abstract
Related Papers
No related papers found
Powered by citation graph analysis